Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of indian visceral leishmaniasis

American Journal of Tropical Medicine and Hygiene

Volumn 80, Issue 5, 2009, Pages 700-703

  Sundar, S ^a,b   Singh, A ^a,b   Agarwal, D ^a,b   Rai, M ^a,b   Agrawal, N ^a,b   Chakravarty, J ^a,b  

^a BANARAS HINDU UNIVERSITY   (India)

^b Kala azar Research Center   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CHLORPHENIRAMINE MALEATE; LIPID EMULSION; PARACETAMOL; AMPHOTERICIN B; LIPID;

ADULT; AGED; ARTICLE; CHILL; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SINGLE DRUG DOSE; VISCERAL LEISHMANIASIS; CHEMISTRY; DOSE RESPONSE; DRUG ADMINISTRATION; EMULSION;

ADULT; AMPHOTERICIN B; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; LIPIDS; MALE; YOUNG ADULT;

EID: 66149103635     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.80.700     Document Type: Article

References (14)

1. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A. Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104-1107.
2. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW, 1997. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 176:1117-1119.
3. Thakur CP, Narayan S, 2004. A comparative evaluation of ampho-tericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98:129-138.
4. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356:2571-2581.
5. Sundar S, Rai M, 2005. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 2821-2829.
6. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323:419-422.
7. Sundar S, Chakravarty J, Agarwal D, Shah A, Agarwal N, Rai M, 2008. Safety of a preformed amphotericin B lipid emulsion for the treat-ment of Indian kala-azar. Trop Med Int Health 13:1208-1212.
8. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
9. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479.
10. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Bethesda, MD: National Cancer Institute. Available at: http://ctep.cancer.gov/protocolDevelop ment/electronic-applications/docs/ ctcaev3.pdf.
11. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37:800-804.
12. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, 2002. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66:143-146.
13. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniaasis: conventional versus lipid formulations. Clin Infect Dis 38: 377-383.
14. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW, 2008. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oal mltefosine. Clin Infect Dis 47: 1000-1006.